These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 21159721)

  • 21. CSF chitinase proteins in amyotrophic lateral sclerosis.
    Thompson AG; Gray E; Bampton A; Raciborska D; Talbot K; Turner MR
    J Neurol Neurosurg Psychiatry; 2019 Nov; 90(11):1215-1220. PubMed ID: 31123140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum and cerebrospinal fluid concentrations of homoarginine, arginine, asymmetric and symmetric dimethylarginine, nitrite and nitrate in patients with multiple sclerosis and neuromyelitis optica.
    Haghikia A; Kayacelebi AA; Beckmann B; Hanff E; Gold R; Haghikia A; Tsikas D
    Amino Acids; 2015 Sep; 47(9):1837-45. PubMed ID: 26055922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption.
    Uchida T; Mori M; Uzawa A; Masuda H; Muto M; Ohtani R; Kuwabara S
    Mult Scler; 2017 Jul; 23(8):1072-1084. PubMed ID: 27682231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica.
    Shimizu F; Nishihara H; Sano Y; Takeshita Y; Takahashi S; Maeda T; Takahashi T; Abe M; Koga M; Kanda T
    PLoS One; 2015; 10(3):e0122000. PubMed ID: 25811465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T
    Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis.
    Wang H; Wang K; Wang C; Xu F; Zhong X; Qiu W; Hu X
    Neuroimmunomodulation; 2013; 20(2):113-8. PubMed ID: 23328212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier.
    Hosokawa T; Nakajima H; Doi Y; Sugino M; Kimura F; Hanafusa T; Takahashi T
    J Neuroimmunol; 2011 Jul; 236(1-2):81-6. PubMed ID: 21621856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
    Comabella M; Deutschmann C; Midaglia L; Schierack P; Martínez J; Roggenbuck D; Montalban X
    Mult Scler; 2021 Aug; 27(9):1455-1457. PubMed ID: 33327838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability.
    Tomizawa Y; Yokoyama K; Saiki S; Takahashi T; Matsuoka J; Hattori N
    J Int Med Res; 2012; 40(4):1483-91. PubMed ID: 22971500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of serum gamma-glutamyltransferase and C-reactive proteins with neuromyelitis optica and multiple sclerosis.
    Shu Y; Li R; Qiu W; Chang Y; Sun X; Fang L; Chen C; Yang Y; Lu Z; Hu X; Kermode AG
    Mult Scler Relat Disord; 2017 Nov; 18():65-70. PubMed ID: 29107207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracellular miR-145, miR-223 and miR-326 expression signature allow for differential diagnosis of immune-mediated neuroinflammatory diseases.
    Sharaf-Eldin WE; Kishk NA; Gad YZ; Hassan H; Ali MAM; Zaki MS; Mohamed MR; Essawi ML
    J Neurol Sci; 2017 Dec; 383():188-198. PubMed ID: 29246612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid IL-21 levels in Neuromyelitis Optica and multiple sclerosis.
    Wu A; Zhong X; Wang H; Xu W; Cheng C; Dai Y; Bao J; Qiu W; Lu Z; Hu X
    Can J Neurol Sci; 2012 Nov; 39(6):813-20. PubMed ID: 23041403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica.
    Wang H; Wang K; Zhong X; Dai Y; Qiu W; Wu A; Hu X
    Neuroimmunomodulation; 2012; 19(5):304-8. PubMed ID: 22777162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
    Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.
    Comabella M; Fernández M; Martin R; Rivera-Vallvé S; Borrás E; Chiva C; Julià E; Rovira A; Cantó E; Alvarez-Cermeño JC; Villar LM; Tintoré M; Montalban X
    Brain; 2010 Apr; 133(Pt 4):1082-93. PubMed ID: 20237129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal Fluid Level of Soluble CD27 Is Associated with Disease Severity in Neuromyelitis Optica Spectrum Disorder.
    Liu B; Zhong X; Lu Z; Qiu W; Hu X; Wang H
    Neuroimmunomodulation; 2018; 25(4):185-192. PubMed ID: 30423585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FTY720 Exacerbates Blood-Brain Barrier Dysfunction Induced by IgG Derived from Patients with NMO and MOG Disease.
    Yoshimura S; Nakagawa S; Takahashi T; Tanaka K; Tsujino A
    Neurotox Res; 2021 Aug; 39(4):1300-1309. PubMed ID: 33999356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
    Narikawa K; Misu T; Fujihara K; Nakashima I; Sato S; Itoyama Y
    J Neuroimmunol; 2004 Apr; 149(1-2):182-6. PubMed ID: 15020078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increase in multiple sclerosis activity after assisted reproduction technology.
    Correale J; Farez MF; Ysrraelit MC
    Ann Neurol; 2012 Nov; 72(5):682-94. PubMed ID: 23034952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.